Recor Medical's Paradise Ultrasound Renal Denervation System Named Best Invention of 2026

Palo Alto, CA, Oct. 15, 2026 /CourierPR/ -- Recor Medical, Inc., a subsidiary of Otsuka Medical Devices Co., Ltd., has been recognized for its Paradise™ Ultrasound Renal Denervation (uRDN) system, which has been named one of the Best Inventions of 2026 by TIME. The award places the Paradise uRDN system in the Medical and Healthcare category, highlighting its significance in the field of medical technology.

For over two decades, TIME has been honoring innovations that are transforming how people live, work, and approach healthcare. This year, the publication compiled a list of 300 extraordinary inventions, selecting the Paradise uRDN system based on its originality, efficacy, ambition, and impact. The system is designed to address uncontrolled and resistant hypertension, a condition often referred to as "the Silent Killer," which can lead to serious cardiovascular issues such as heart attacks and strokes.

The Paradise uRDN system works by delivering two to three doses of 360-degree ultrasound energy, each lasting seven seconds, through the main renal arteries to the surrounding nerves. This process denervates the sympathetic nerves, reducing their overactivity and thereby lowering blood pressure. The system features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall.

The Paradise uRDN system has received FDA approval in November 2023 and is currently commercially available in the United States. It is indicated as an adjunctive treatment for hypertension patients whose blood pressure cannot be adequately controlled through lifestyle modifications and antihypertensive medications. The system is CE 2797 marked and approved in markets where the CE 2797 mark is accepted, per approved indications for use. Additionally, the Paradise uRDN system has received regulatory approval in Japan.

Clinical evidence for the Paradise uRDN system includes positive outcomes in three independent, randomized, sham-controlled studies conducted in patients with mild-to-moderate and resistant hypertension. Recor Medical is also advancing real-world evidence generation through the Global Paradise System (GPS) Registry in the European Union and the UK, as well as the US GPS post-approval study in the United States.

The Paradise uRDN system represents a significant step forward in the management of treatment-resistant hypertension, offering a minimally invasive procedure that could potentially improve the lives of many patients worldwide.